Medicare Part D payments for brand and generic drugs prescribed by dermatologists
To the Editor: Rising drug costs are a concerning trend in dermatology and health care in general. 1 Increased utilization of generic alternatives to brand medications is often proposed as a way to reduce costs. 2 Between 2003 and 2012, generic drug use reportedly saved Americans $1.2 trillion. 3 Given these potential savings, understanding trends in generic and brand prescribing patterns is important, but little is known about these patterns among dermatologists in the Medicare population. A recent analysis of Medicare Part D prescription payments in 2013 reported that dermatologists prescribed the lowest proportion of brand name drugs among 30 specialties studied. 4 Although this study investigated general patterns of brand versus generic prescribing, to our knowledge, no studies have specifically investigated patterns and associated costs of generic and brand prescriptions among dermatologists.
We performed a cross-sectional analysis of population-based claims data from the 2015 Medicare Part D Prescriber Public Use and Summary files, which contain prescription brand name, generic name, claim count (including refills), and total Medicare spending organized by National Provider Identifier. All generic and branded medications prescribed by dermatologists were identified. Dermatologist-prescribed medications were divided into 7 classes: anti-infectives, antihistamines, biologics, immunomodulators, retinoids, topical steroids, and other. Medication classes included all routes of administration (oral, topical, and injection) unless otherwise stated. Drugs were designated as generic if the generic name variable matched the brand name variable in the data set. In instances in which syntax differed between brand and generic variables, for example, ''acetaminophen-codeine'' (brand variable) ¼ ''acetaminophen with codeine'' ( generic variable), we reclassified the medication as generic to avoid misclassification.
Statistical analysis was performed with Stata/MP 15.0 software (StataCorp, College Station, TX). Summary statistics were calculated for number of providers, total costs and claims per medication, total brand costs and claims, and proportion brand costs and claims. Dermatologists comprised 11,769 of all providers(1.4%) and accounted for 6,170,605 (0.5%) prescription claims and $841,534,934 (0.8%) of total drug cost. Among prescriptions by dermatologists, 158,232 (2.56%) were for brand medications, which accounted for 44% of the total cost. Topical steroids accounted for both the highest proportion of total claims (41.8%) and total cost (30.1%). Biologics accounted for the lowest proportion of total claims (0.9%) but the second-highest proportion of total cost (30.0%) ( Table I) . A small percentage of dermatologists prescribed among the costliest medications (Table II) . Less than half (35.6%) of dermatology providers accounted for all brandname prescriptions.
Dermatologists represent a small percentage of Medicare prescribers and accounted for an even smaller proportion of Medicare Part D drug costs. Compared with other specialists, dermatologists have low rates of prescribing brand medications, commonly prescribing biologics without generic alternatives. 4 Although increasing generic drug utilization is touted as a way to reduce Medicare costs, dermatologists have little room to improve, as 97.4% of the drugs they prescribe are generics. Our results further highlight the fact that cost of generic medications is an important source of rising medication costs in dermatology. In 2013, Canoui-Poitrine et al were the first to propose phenotypes and identified 3 phenotypes on the basis of latent class analysis of a database containing 618 HS patients. 2 For detailed characteristics of the 3 identified phenotypes (axillary-mammary type, follicular type, and gluteal type) see Table I . The Canoui-Poitrine phenotypes have not been validated in clinical practice or used in clinical trials. Therefore, the aim of this study was to evaluate their interrater reliability in a clinical setting.
In 2017, thirty real-life cases were randomly selected from the population seen at the Department of Dermatology, Erasmus Medical Center, Rotterdam, The Netherlands, during March 2016-July 2017. Subsequently, the 30 cases were anonymized and digitalized by an author (Verhagen), who did not participate in the scoring of the cases. The following parameters, which were required to distinguish the 3 proposed phenotypes, were presented digitally: lesion types (hypertrophic scars, epidermal cysts, comedones papules, folliculitis); affected areas; disease duration; Hurley staging; sex; co-morbidities ( pilonidal sinus, acne); smoking status; and body mass index.
A panel of 8 Dutch HS experts (5 dermatologists and 3 graduate students with extensive clinical experience with HS) were supplied with detailed information on the Canoui-Poitrine phenotypes. All experts, independently and without conferring, assigned a phenotype to each of these digital cases. The Guidelines for Reporting Reliability and Agreement Studies were used as a basis for the design and documentation of this interrater reliability study. 3 The interrater reliability was calculated as a Fleiss' kappa. For the interpretation of the kappa values, the benchmarks proposed by Landis and Koch were used. 4 For this type of investigation, no medical ethical committee approval is required under Dutch law.
The assessors agreed on the same Canoui-Poitrine phenotype for only 23.3% of cases, and the phenotypes reached a of 0.37 (95% confidence interval 0.32-0.42), indicating slight interrater reliability (Fig 1) . Canoui-Poitrine et al stated that their classification is legitimate, as the phenotypes fit with typical and atypical clinical observations. However, in our view, while subtyping HS patients by CanouiPoitrine phenotype might be useful at a population level, it does not appear to be applicable at the individual level in daily practice. In our experience, characteristics from [1 phenotype are often present in the same patient, restricting straightforward classification. An effort to divide HS patients into clinical subtypes has been performed by van der Zee et al. 5 However, these phenotypes are yet to be evaluated.
In summary, the HS phenotypes proposed by Canoui-Poitrine et al reached only slight interrater reliability. We, therefore, conclude that CanouiPoitrine phenotypes are of limited use in clinical practice and research setting. Therefore a new subset of HS phenotypes is required. 
